Skip to main content
Premium Trial:

Request an Annual Quote

Researchers Solve 3D Structure of Anthrax Toxin/Host Cell Complex

NEW YORK, July 6 (GenomeWeb News) - Scientists at the Burnham Institute have determined the x-ray crystal structure of an anthrax toxin protein docked to a host cell receptor - a complex that governs the entry of the anthrax toxin into human cells.

 

The results of the study, published in the online version of the journal Nature on July 4, could provide new targets for anthrax antitoxins, as well as point the way toward engineered anthrax toxin molecules that would selectively attack tumor cells, the researchers said.

 

The study was funded by the National Institute of Allergy and Infectious Diseases and led by Robert Liddington of the Burnham Institute in La Jolla, Calif.

 

Anthrax toxin uses a protein known as protective antigen to bind to two different cell receptors: CMG2 and TEM8. The Burnham Institute team solved the 3D structure of the protective antigen protein/CMG2 complex. While previous studies had determined the 3D structures of the unbound anthrax protective antigen protein and the CMG2 receptor separately, the researchers said that the protein complex offers clearer targets for researchers working on anthrax antitoxins.

 

In addition, Liddington said that the structure could lead to a potential new tumor treatment using a genetically modified anthrax toxin based on the TEM8 cell receptor. Although the structure of the TEM8 receptor has not been determined, "Computer modeling could enable us to design a version of the anthrax toxin that binds only to TEM8 and not to CMG2," which would kill tumor cells while leaving ordinary cells intact, Liddington said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more